Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 846-851

  Juan, Carlos ^a   Zamorano, Laura ^a   Pérez, José L ^a   Ge, Yigong ^b   Oliver, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b Calixa Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CXA 101; EXTENDED SPECTRUM BETA LACTAMASE; FR 264205; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG; W 159R;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; GENE SEQUENCE; ISOELECTRIC FOCUSING; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPAIN;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; ISOELECTRIC FOCUSING; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 75749148334     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00834-09     Document Type: Article

References (41)

1. Brown, N. P., C. M. Pillar, D. F. Sham, and Y. Ge. 2009. Activity profile of CXA-101 and CXA-101/tazobactam against target Gram-positive and Gramnegative pathogens, abstr. F1-1986. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
2. Cavallo, J. D., D. Hocquet, P. Plesiat, R. Fabre, and M. Roussel-Delvallez. 2007. Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. J. Antimicrob. Chemother. 59:1021-1024.
3. Coque, T. M., A. Oliver, J. C. Perez-Diaz, F. Baquero, and R. Canton. 2002. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum betalactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob. Agents Chemother. 46:500-510.
4. Deplano, A., O. Denis, L. Poirel, D. Hocquet, C. Nonhoff, B. Byl, P. Nordmann, J. L. Vincent, and M. J. Struelens. 2005. Molecular characterization of an epidemic clone of panantibiotic resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 43:1198-1204.
5. El Amin, N., C. G. Giske, S. Jalal, B. Keijser, G. Kronvall, and B. Wretlind. 2005. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 113:187-196.
6. Empel, J., K. Filczak, A. Mrowka, W. Hryniewicz, D. M. Livermore, and M. Gniadkowski. 2007. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum β-lactamase in Warsaw, Poland: further evidence for an internacional clonal complex. J. Clin. Microbiol. 45:2829-2834.
7. Giske, C. G., J. Ge, and P. Nordmann. 2009. Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum- β-lactamase-producing Pseudomonas aeruginosa. J. Antimicrob. Chemother. 64: 430-431.
8. Gutiérrez, O., C. Juan, E. Cercenado, F. Navarro, E. Bouza, P. Coll, J. L. Pérez, and A. Oliver. 2007. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob. Agents Chemother. 51:4329-4335.
9. Hocquet, D., P. Berthelot, M. Roussel-Delvallez, R. Favre, K. Jeannot, O. Bajolet, N. Marty, F. Grattard, P. Mariani-Kurkdjan, E. Bingen, M. O. Housson, G. Couetdic, and P. Plesiat. 2007. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob. Agents Chemother. 51:3531-3536.
10. Juan, C., M. D. Maciá, O. Gutiérrez, C. Vidal, J. L. Pérez, and A. Oliver. 2005. Molecular mechanisms of β-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 49:4733-4738.
11. Juan, C., X. Mulet, L. Zamorano, S. Alberti, J. L. Peréz, and A. Oliver. 2009. Detection of the novel extended spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates in Spain. Antimicrob. Agents Chemother. 53:5288-5290.
12. VIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 43:1584-1590.
13. Leibovici, L., I. Shraga, M. Drucker, H. Konigsberger, Z. Samra, and S. D. Pitliks. 1998. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J. Intern. Med. 244:379-386.
14. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
15. Livermore, D. M., S. Mushtaq, Y. Ge, and M. Wagner. 2009. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderhia cepacia group strains and isolates. Int. J. Antimicrob. Agents. 34:402-406.
16. Luzzaro, F., E. Mantengoli, M. Perilli, G. Lombardi, V. Orlandi, A. Orsatti, G. Amicosante, G. M. Rossolini, and A. Tolino. 2001. Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extendend-spectrum β-lactamase. J. Clin. Microbiol. 39:1865-1870.
17. Masuda, N., E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXYOprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327.
18. Mesaros, N., P. Nordmann, P. Plesiat, M. Roussel-Delvallez, J. Van Eldere, Y. Glupczynski, Y. van Laethem, F. Jacobs, P. Lebesque, A. Malfroot, P. M. Tulkens, and F. van Bambeke. 2007. Pseudomonas aeruginosa: resistance and therapeutics options in the turn of the new millennium. Clin. Microbiol. Infect. 13:560-578.
19. Moya, B., A. Döstch, C. Juan, J. Blázquez, L. Zamorano, S. Haussler, and A. Oliver. 2009. β-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PloS Pathog. 5:e1000353.
20. Obritsch, M. D., D. N. Fish, R. MacLaren, and R. Jung. 2004. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48:4606-4610.
21. Oliver, A., L. M. Weigel, J. K. Rasheed, J. E. McGowan, P. Raney, and F. C. Tenover. 2002. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob. Agents Chemother. 46:3829-3836.
22. Peña, C., C. Suárez, F. Tubau, O. Gutiérrez, A. Domínguez, A. Oliver, M. Pujol, F. Gudiol, and J. Ariza. 2007. Nosocomial spread of Pseudomonas aeruginosa producing the metallo-β-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. Clin. Microbiol. Infect. 13:1026-1029.
23. Pirnay, J. P., D. de Vos, D. Mossialos, A. Vanderkelen, P. Cornelis, and M. Zizi. 2002. Analysis of the Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ. Microbiol. 4:872-882.
24. Poirel, L., T. Naas, D. Nicolas, L. Collet, S. Bellais, J. D. Cavallo, and P. Nordmann. 2000. Characterization of VIM-2, a carbapenem-hydrolyzing metallo β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44:891-897.
25. Poirel, L., D. Girlich, T. Nass, and P. Nordmann. 2001. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob. Agents Chemother. 45:447-453.
26. Poirel, L., L. Cabanne, H. Vahaboglu, and P. Nordmann. 2005. Genetic environment and expression of the extended-spectrum β-lactamase blaPER-1 gene in gram-negative bacteria. Antimicrob. Agents Chemother. 49:1708-1713.
27. Poirel, L., L. Brinas, A. Verlinde, L. Ide, and P. Nordmann. 2005. BEL-1, a novel clavulanic acid-inhibited extendend-spectrum β-lactamase, and the class 1 integron In20 in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:3743-3748.
28. Poole, K. 2004. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect. 10:12-26.
29. VIM-4. J. Antimicrob. Chemother. 51:1409-1414.
30. Quale, J., S. Bratu, J. Gupta, and D. Landman. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641.
31. VIM-1-containing integron carrying a new aminoglycoside phosphotransferase gene cassette. Antimicrob. Agents Chemother. 45: 1249-1253.
32. Rossolini, G. M., F. Luzzaro, R. Migliavacca, C. Mugnaioli, B. Pini, F. De Luca, M. Perilli, S. Pollini, M. Spalla, G. Amicosante, A. Toniolo, and L. Pagani. 2008. First countrywide survey of acquired metallo-β- lactamases in gram-negative pathogens in Italy. Antimicrob. Agents Chemother. 52:4023-4029.
33. Sánchez-Romero, I., E. Cercenado, O. Cuevas, N. García-Escribano, J. García-Martínez, E. Bouza, and the Spanish Group for the Study of Pseudomonas aeruginosa. 2007. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: second national study (2003). Rev. Esp. Quimioter. 20:222-229.
34. Smith, A. W., and B. H. Iglewski. 1989. Transformation of Pseudomonas aeruginosa by electroporation. Nucleic Acids Res. 17:10509.
35. Takeda, S., Y. Ishii, K. Hatano, K. Tateda, and K. Yamaguchi. 2007. Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 30:443-445.
36. Takeda, S., T. Nakai, Y. Wakai, F. Ikeda, and K. Hatano. 2007. In vitro and In vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51:826-830.
37. Tato, M., A. Valverde, T. M. Coque, and R. Cantón. 2006. PER-1 multiresistant Pseudomonas aeruginosa strain in Spain. Enferm. Infecc. Microbiol. Clin. 24:472-473.
38. Viedma, E., C. Juan, J. Acosta, L. Zamorano, J. Otero, F. Sanz, F. Chaves, and A. Oliver. 2009. Nosocomial spread of colistin-only-sensitive ST235 Pseudomonas aeruginosa isolates producing the extended-spectrum β-lactamases GES-1 and GES-5 in Spain. Antimicrob. Agents Chemother. 53:4930-4933.
39. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallobeta-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306-325.
40. West, S. E., H. P. Schweizer, C. Dall, A. K. Sample, and L. J. Runyen-Janecky. 1994. Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa. Gene 148:81-86.
41. Wolter, D. J., N. D. Hanson, and P. D. Lister. 2004. Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol. Lett. 236:137-143.